Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Acta Ophthalmol ; 98(4): 360-367, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31656056

RESUMEN

PURPOSE: To evaluate visual acuity (VA) and central retinal thickness (CRT) on optical coherence tomography during a 4-year period in patients treated for sight-threatening diabetic macular oedema (DMO) at two Swedish county hospitals. Additionally, to compare health-related quality of life and subjective visual functioning before and after 4 years of treatment. METHODS: Fifty-eight patients with DMO were evaluated after 4 years of antivascular endothelial growth factor (VEGF) treatment. VA, CRT and clinical data were retrospectively reviewed. Health-related quality of life and subjective visual functioning were evaluated with Short Form Health Survey (SF-36) and National Eye Institute Vision Functioning Questionnaire 25 (VFQ-25). Comparisons between independent groups were performed using Pearson's χ2 test, Fisher's exact test or Mann-Whitney U test. Spearman's ρ was used for correlation analyses. Wilcoxon signed-rank test was used for comparison between dependent groups. Logistic regression analysis was applied for analysis of VA and CRT over 4 years. RESULTS: Follow-up data were obtained from 37 of 58 (63.8%) patients. Baseline characteristics were similar, regardless of follow-up. VA improvement at 1 year (mean + 4.4, SD 7.5; ETDRS letter score) was maintained over 3 years, then declined. CRT was reduced throughout the study. In the first treatment year, eyes received 5.1 (1.4) anti-VEGF injections, followed by approximately two injections yearly. Additional treatment included laser and dexamethasone implants. SF-36 showed no change at 4 years, compared with baseline. VFQ-25 demonstrated improvement in near vision activities (p = 0.036). CONCLUSION: Significant long-term improvement in visual function was present in patients with anti-VEGF-treated DMO.


Asunto(s)
Inhibidores de la Angiogénesis/administración & dosificación , Retinopatía Diabética/tratamiento farmacológico , Mácula Lútea/patología , Edema Macular/tratamiento farmacológico , Tomografía de Coherencia Óptica/métodos , Agudeza Visual , Bevacizumab/administración & dosificación , Retinopatía Diabética/complicaciones , Retinopatía Diabética/diagnóstico , Estudios de Seguimiento , Humanos , Inyecciones Intravítreas , Edema Macular/diagnóstico , Edema Macular/etiología , Estudios Prospectivos , Calidad de Vida , Ranibizumab/administración & dosificación , Factores de Tiempo , Resultado del Tratamiento , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores
2.
BMJ Open Diabetes Res Care ; 5(1): e000432, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-29225894

RESUMEN

OBJECTIVE: Guided Self-Determination (GSD) is a person-centered communication and reflection method. Education in groups may have a greater impact than the content of the education, and constructive communication between parents and adolescents has been shown to be of importance. The purpose of this study was to describe adolescents' perceptions of participation in group education with the Guided Self-Determination-Young (GSD-Y) method, together with parents, in connection with the introduction of continuous subcutaneous insulin infusion. RESEARCH DESIGN AND METHODS: In the present qualitative interview study, 13 adolescents with type 1 diabetes were included after completing a GSD-Y group education program in connection with the introduction of continuous subcutaneous insulin infusion at three hospitals located in central Sweden. The adolescents were interviewed individually, and qualitative content analysis was applied to the interview transcripts. RESULTS: Two categories that emerged from the analysis were the importance of context and growing in power through the group process. An overarching theme that emerged from the interviews was the importance of expert and referent power in growing awareness of the importance of self-management as well as mitigating the loneliness of diabetes. CONCLUSIONS: GSD-Y has, in various ways, mitigated experiences of loneliness and contributed to conscious reflection about self-management in the group (referent power) together with the group leader (expert power). Overall, this highlights the benefits of group education, and the GSD method emphasizes the person-centered approach. TRIAL REGISTRATION NUMBER: ISRCTN22444034; Results.

3.
Diabetes Res Clin Pract ; 121: 157-165, 2016 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27718374

RESUMEN

AIMS: To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), patient reported outcome and describe levels of glycated hemoglobin and its association with the effects on visual acuity in patients treated with anti-VEGF for visual impairment due to diabetic macular edema (DME) during 12months in a real world setting. METHODS: In this cross-sectional study, 58 patients (29 females and 29 males; mean age, 68years) with type 1 and type 2 diabetes diagnosed with DME were included. Medical data and two questionnaires were collected; an eye-specific (NEI VFQ-25) and a generic health-related quality of life questionnaire (SF-36) were used. RESULTS: The total patient group had significantly improved visual acuity and reduced retinal thickness at 4months and remains at 12months follow up. Thirty patients had significantly improved visual acuity, and 27 patients had no improved visual acuity at 12months. The patients with improved visual acuity had significantly improved scores for NEI VFQ-25 subscales including general health, general vision, near activities, distance activities, and composite score, but no significant changes in scores were found in the group without improvements in visual acuity. CONCLUSIONS: Our study revealed that anti-VEGF treatment improved visual acuity and central retinal thickness as well as patient-reported outcome in real world 12months after treatment start.


Asunto(s)
Diabetes Mellitus Tipo 2/complicaciones , Retinopatía Diabética/complicaciones , Edema Macular/tratamiento farmacológico , Medición de Resultados Informados por el Paciente , Calidad de Vida , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Agudeza Visual , Anciano , Anciano de 80 o más Años , Estudios Transversales , Retinopatía Diabética/tratamiento farmacológico , Retinopatía Diabética/fisiopatología , Femenino , Estudios de Seguimiento , Hemoglobina Glucada/metabolismo , Humanos , Edema Macular/etiología , Edema Macular/fisiopatología , Masculino , Persona de Mediana Edad , Retina/diagnóstico por imagen , Retina/efectos de los fármacos , Encuestas y Cuestionarios , Factores de Tiempo , Tomografía de Coherencia Óptica , Resultado del Tratamiento
4.
J Diabetes Complications ; 29(8): 1183-90, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26318959

RESUMEN

PURPOSE: To examine patient-reported outcome (PRO) in a selected group of Swedish patients about to receive anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME). MATERIAL AND METHODS: In this cross-sectional study, 59 patients with diabetes mellitus, who regularly visited the outpatient eye-clinics, were included. Sociodemographic and clinical data were collected and the patients completed PRO measures before starting anti-VEGF treatment. PRO measures assessed eye-specific outcomes (NEI-VFQ-25) and generic health-related quality of life (SF-36). RESULTS: The participants consisted of 30 men and 29 women (mean age, 68.5years); 54 (92%) patients had type 2 diabetes; 5 (9%) patients had moderate or severe visual impairment; 28 (47%) were classified as having mild visual impairment. Some of the patients reported overall problems in their daily lives, such as with social relationships, as well as problems with impaired sight as a result of reduced distance vision. CONCLUSIONS: Further studies are needed to investigate PRO factors related to low perceived general health in this patient population. It is important to increase our understanding of such underlying mechanisms to promote improvements in the quality of patient care.


Asunto(s)
Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 2/complicaciones , Retinopatía Diabética/fisiopatología , Edema Macular/fisiopatología , Calidad de Vida , Estrés Psicológico/fisiopatología , Agudeza Visual , Inhibidores de la Angiogénesis/efectos adversos , Inhibidores de la Angiogénesis/uso terapéutico , Actitud Frente a la Salud , Ceguera/inducido químicamente , Ceguera/epidemiología , Ceguera/etiología , Estudios de Cohortes , Estudios Transversales , Retinopatía Diabética/tratamiento farmacológico , Retinopatía Diabética/psicología , Femenino , Humanos , Edema Macular/complicaciones , Edema Macular/tratamiento farmacológico , Edema Macular/psicología , Masculino , Persona de Mediana Edad , Ranibizumab/efectos adversos , Ranibizumab/uso terapéutico , Riesgo , Autoinforme , Índice de Severidad de la Enfermedad , Estrés Psicológico/complicaciones , Estrés Psicológico/etiología , Suecia/epidemiología , Factores de Crecimiento Endotelial Vascular/antagonistas & inhibidores
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA